CCL5 and breast cancer: A higher plasma CCL5 was inversely associated with breast cancer (OR = 0.89, 95% CI: 0.85 to 0.94, p < 0.001), which was primarily attributed to the luminal A and luminal B subtypes (OR for luminal A = 0.88, 95% CI: 0.82 to 0.94; OR for luminal B = 0.80, 95% CI: 0.69–0.94).